Raymond Davidson, MD
Psychiatry · Honolulu, HINPI 1790981884
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 30.8% of the total. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$679
- Sunovion Pharmaceuticals Inc.$612
- Indivior Inc.$586
- Alkermes, Inc.$274
- plus $554 from 6 others
What the payments were for
- Food & beverage$5,88498%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $1,845 |
| Teva Pharmaceuticals USA, Inc. | 57 | $1,444 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $679 |
| Sunovion Pharmaceuticals Inc. | 38 | $612 |
| Indivior Inc. | 22 | $586 |
| Alkermes, Inc. | 9 | $274 |
| Otsuka America Pharmaceutical, Inc. | 7 | $259 |
| Johnson & Johnson | 4 | $109 |
| Avanir Pharmaceuticals, Inc. | 1 | $102 |
| Neuronetics, Inc. | 1 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$481
- ABILIFY MAINTENA$147
- ABILIFY ASIMTUFII$147
- ARISTADA INITIO$120
- NUEDEXTA$102
How this compares
$5,993 in reported general payments places this provider in the 95th percentile of 183 psychiatry providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 145 | $450,987 |
| Abilify MaintenaAripiprazole | 119 | $341,200 |
| AustedoDeutetrabenazine | 40 | $317,433 |
| Invega TrinzaPaliperidone Palmitate | 21 | $201,671 |
| PerserisRisperidone | 28 | $80,608 |
| VraylarCariprazine Hcl | 34 | $66,244 |
| UzedyRisperidone | 15 | $54,749 |
| AristadaAripiprazole Lauroxil | 13 | $42,352 |
| Quetiapine Fumarate | 998 | $34,378 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $23,242 |
| Clozapine | 309 | $22,090 |
| Chlorpromazine Hcl | 51 | $16,633 |
| Risperidone | 589 | $16,392 |
| Divalproex Sodium ErDivalproex Sodium | 196 | $12,545 |
| FanaptIloperidone | 11 | $12,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $109 | $652,659166 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,444 | $372,18255 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $259 | $341,200119 claims |
| Indivior Inc.Perseris | $586 | $80,60828 claims |
| AbbVieVraylar | $1,845 | $66,24434 claims |
| Alkermes, Inc.Aristada, Lybalvi | $274 | $65,59426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $33 | $16,99338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 psychiatry providers in Hawaii.
Other psychiatry in Honolulu
- Denis Mee-LeeHonolulu$526K
- David SteinHonolulu$186K
- Gregory YuenHonolulu$6K
- Helen Blaisdell-BrennanHonolulu$6K
- Glorifin BelmonteHonolulu$5K
- Brett LuHonolulu$5K
- Donna McBrien SliwowskiHonolulu$4K
- Alan BuffensteinHonolulu$3K
- Nancy LuckieHonolulu$3K
- Angela KingHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.